Drug intelligence / Profile preview

MUMO-1

Development stage: Unknown
Lead developer: Purdue Pharma
Modality: Small Molecules

Overview

**MUMO-1** is a small molecule σ1 receptor antagonist initially developed by Esteve Pharmaceuticals SA for nervous system diseases, particularly pain-related conditions. It targets the σ1 receptor (also known as the sigma opioid receptor), modulating its activity to potentially alleviate pain through antagonism. The drug has reached Phase 1 in clinical development, with focus on its role in pain management within therapeutic areas of nervous system disorders.[1][13]

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on MUMO-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUMO-1.

Explore the full profile